Technical Analysis for JANX - Janux Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 45.02 | 1.92% | 0.85 |
JANX closed up 1.92 percent on Friday, October 4, 2024, on 74 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Support | Bullish | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Crossed Above 50 DMA | Bullish | 1.92% | |
| Oversold Stochastic | Weakness | 1.92% | |
| Fell Below 50 DMA | Bearish | 3.61% | |
| NR7 | Range Contraction | 3.61% | |
| Stochastic Reached Oversold | Weakness | 3.61% | |
| Inside Day | Range Contraction | 3.61% | |
| Down 3 Days in a Row | Weakness | 3.61% | |
| Down 4 Days in a Row | Weakness | 3.61% |
| Alert | Time |
|---|---|
| 50 DMA Support | about 23 hours ago |
| Down 1% | about 23 hours ago |
| Fell Below 50 DMA | about 23 hours ago |
| 60 Minute Opening Range Breakdown | about 23 hours ago |
| Rose Above Previous Day's High | about 24 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/06/2024
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunology Immune System Tumor Platform Technology Chimeric Antigen Receptor T Cell T Cell Clusters Of Differentiation
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunology Immune System Tumor Platform Technology Chimeric Antigen Receptor T Cell T Cell Clusters Of Differentiation
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 65.6 |
| 52 Week Low | 5.65 |
| Average Volume | 560,376 |
| 200-Day Moving Average | 36.67 |
| 50-Day Moving Average | 43.81 |
| 20-Day Moving Average | 46.88 |
| 10-Day Moving Average | 46.22 |
| Average True Range | 2.74 |
| RSI (14) | 47.37 |
| ADX | 19.78 |
| +DI | 16.53 |
| -DI | 17.74 |
| Chandelier Exit (Long, 3 ATRs) | 44.01 |
| Chandelier Exit (Short, 3 ATRs) | 49.45 |
| Upper Bollinger Bands | 52.01 |
| Lower Bollinger Band | 41.75 |
| Percent B (%b) | 0.32 |
| BandWidth | 21.89 |
| MACD Line | 0.05 |
| MACD Signal Line | 0.72 |
| MACD Histogram | -0.666 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 48.08 | ||||
| Resistance 3 (R3) | 47.89 | 46.69 | 47.57 | ||
| Resistance 2 (R2) | 46.69 | 45.91 | 46.78 | 47.40 | |
| Resistance 1 (R1) | 45.85 | 45.43 | 46.27 | 46.04 | 47.23 |
| Pivot Point | 44.65 | 44.65 | 44.86 | 44.74 | 44.65 |
| Support 1 (S1) | 43.81 | 43.87 | 44.23 | 44.00 | 42.81 |
| Support 2 (S2) | 42.61 | 43.39 | 42.70 | 42.64 | |
| Support 3 (S3) | 41.77 | 42.61 | 42.47 | ||
| Support 4 (S4) | 41.96 |
